Mersana Therapeutics, a clinical-stage biotech developing antibody drug conjugate therapies for cancers, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.
The Cambridge, MA-based company was founded in 2002 and booked $26 million in revenue for the 12 months ended March 31, 2017. It plans to list on the Nasdaq under the symbol MRSN. Mersana Therapeutics filed confidentially on March 17, 2017. J.P. Morgan, Cowen & Company, Leerink Partners and Wedbush PacGrow are the joint bookrunners on the deal. No pricing terms were disclosed.
